Isabelle Dimier-Poisson Selected Research

Antigens

1/2022	Co-delivery of PLGA nanoparticles loaded with rSAG1 antigen and TLR ligands: An efficient vaccine against chronic toxoplasmosis.
1/2021	Neospora caninum glycosylphosphatidylinositols used as adjuvants modulate cellular immune responses induced in vitro by a nanoparticle-based vaccine.
1/2018	Targeted Delivery of Toxoplasma gondii Antigens to Dendritic Cells Promote Immunogenicity and Protective Efficiency against Toxoplasmosis.
5/2015	Porous nanoparticles as delivery system of complex antigens for an effective vaccine against acute and chronic Toxoplasma gondii infection.
8/2010	Interleukin 17 receptor signaling is deleterious during Toxoplasma gondii infection in susceptible BL6 mice.
8/2009	Dendritic cells loaded with HIV-1 p24 proteins adsorbed on surfactant-free anionic PLA nanoparticles induce enhanced cellular immune responses against HIV-1 after vaccination.
11/2007	A vaccine based on exosomes secreted by a dendritic cell line confers protection against T. gondii infection in syngeneic and allogeneic mice.
7/2004	Toxoplasma gondii antigen-pulsed-dendritic cell-derived exosomes induce a protective immune response against T. gondii infection.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Isabelle Dimier-Poisson Research Topics

Disease

16	Toxoplasmosis 01/2023 - 03/2006
9	Infections 01/2023 - 07/2004
7	Congenital Toxoplasmosis 07/2021 - 10/2006
6	Neoplasms (Cancer) 01/2023 - 08/2009
3	Ileitis 01/2020 - 08/2010
3	Inflammation (Inflammations) 01/2019 - 08/2010
2	Cysts 01/2019 - 02/2017
2	Parasitic Diseases (Parasitic Disease) 11/2011 - 11/2007
1	Melanoma (Melanoma, Malignant) 01/2023
1	Neoplasm Metastasis (Metastasis) 01/2023
1	Acquired Immunodeficiency Syndrome (AIDS) 01/2022
1	Lice Infestations (Pediculosis) 01/2021
1	Thymoma (Thymic Carcinoma) 11/2020
1	Babesiosis (Piroplasmosis) 12/2019
1	Necrosis 01/2019
1	Breast Neoplasms (Breast Cancer) 11/2018
1	Hepatitis B 04/2013
1	Scorpion Stings 04/2012
1	Communicable Diseases (Infectious Diseases) 08/2009

Drug/Important Bio-Agent (IBA)

14	VaccinesIBA 01/2023 - 10/2006
8	AntigensIBA 01/2022 - 07/2004
4	CytokinesIBA 12/2020 - 01/2019
2	pyridazineIBA 07/2021 - 01/2018
2	SaltsIBA 07/2021 - 01/2018
2	calcium-dependent protein kinaseIBA 07/2021 - 01/2018
2	SP230IBA 07/2021 - 01/2018
2	AntibodiesIBA 01/2021 - 02/2017
2	Neutralizing AntibodiesIBA 01/2021 - 01/2019
2	InterferonsIBA 11/2020 - 08/2010
2	Interleukin-22 (IL-22)IBA 01/2020 - 01/2019
2	Immunoglobulin G (IgG)IBA 11/2018 - 02/2017
2	Interleukin-10 (Interleukin 10)IBA 02/2017 - 08/2010
2	A-Form DNA (A-DNA)IBA 02/2017 - 11/2011
2	Recombinant ProteinsIBA 02/2017 - 11/2011
1	SolutionsIBA 01/2023
1	Interleukin-15 (Interleukin 15)IBA 01/2023
1	LigandsIBA 01/2022
1	Imiquimod (Aldara)FDA LinkGeneric 01/2022
1	Polylactic Acid-Polyglycolic Acid CopolymerIBA 01/2022
1	Immunologic Factors (Immunomodulators)IBA 01/2022
1	Therapeutic UsesIBA 01/2022
1	monophosphoryl lipid AIBA 01/2022
1	lotilanerIBA 01/2021
1	Single-Chain AntibodiesIBA 01/2021
1	Membrane Proteins (Integral Membrane Proteins)IBA 01/2021
1	Immunoglobulins (Immunoglobulin)IBA 01/2021
1	Ivermectin (Mectizan)FDA Link 01/2021
1	Immunoglobulin FragmentsIBA 01/2021
1	talimogene laherparepvecIBA 11/2020
1	Interleukin-33IBA 01/2019
1	Interleukin-12 (IL 12)IBA 01/2019
1	Immunoconjugates (Immunoconjugate)IBA 11/2018
1	maleimideIBA 11/2018
1	PyridazinesIBA 01/2018
1	Interleukin-5 (Interleukin 5)IBA 02/2017
1	Subunit VaccinesIBA 02/2017
1	Immunoglobulin A (IgA)IBA 02/2017
1	Poly I-CIBA 02/2017
1	Interleukin-2 (IL2)IBA 02/2017
1	DNA (Deoxyribonucleic Acid)IBA 02/2017
1	Phosphotransferases (Kinase)IBA 02/2017
1	Cholera ToxinIBA 02/2017
1	Monatide (IMS 3015)IBA 02/2017
1	Virulence Factors (Pathogenicity Factors)IBA 02/2017
1	Proteins (Proteins, Gene)FDA Link 01/2017
1	NanovaccinesIBA 01/2017
1	Protein SIBA 04/2013
1	Interleukin-1 (Interleukin 1)IBA 01/2013
1	VenomsIBA 04/2012
1	Antivenins (Antivenoms)IBA 04/2012
1	Monoclonal AntibodiesIBA 03/2012
1	Interleukin-17 (Interleukin 17)IBA 08/2010
1	InterleukinsIBA 08/2010
1	Interleukin-17 ReceptorsIBA 08/2010
1	DNA VaccinesIBA 05/2009
1	Nucleic AcidsIBA 11/2007
1	RNA (Ribonucleic Acid)IBA 03/2006

Therapy/Procedure

2	Immunotherapy 01/2023 - 11/2020
2	Therapeutics 01/2022 - 11/2020
1	Intranasal Administration 01/2023
1	Transplantation 01/2022
1	Subcutaneous Injections 11/2020
1	Drug Therapy (Chemotherapy) 11/2018
1	Intraperitoneal Injections 09/2015
1	Injections 03/2012
1	Cell- and Tissue-Based Therapy (Cell Therapy) 08/2009